AffaMed Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing transformative pharmaceutical products to address significant unmet medical needs in ophthalmic, neurological, and psychiatric disorders. Co-founded and incubated by CBC Group, AffaMed leverages its robust R&D capabilities and strategic partnerships to advance a diverse pipeline of therapies, with a primary focus on patients in Greater China and a vision for global impact. Their approach emphasizes scientific innovation, clinical excellence, and a patient-first mindset.
The Shanghai headquarters serves as the core for strategic leadership, research and development program management, business development for the Greater China region, and overall corporate operations.
Situated in a modern biopharmaceutical park in Pudong, the headquarters benefits from state-of-the-art facilities and proximity to a rich ecosystem of research institutions, talent, and potential collaborators.
AffaMed cultivates a work environment that is innovative, collaborative, and results-driven. There's a strong emphasis on scientific rigor, ethical conduct, and a shared passion for making a difference in patients' lives.
The Shanghai headquarters is crucial for AffaMed's mission, anchoring its operations in one of the world's fastest-growing healthcare markets and serving as a bridge for global drug development efforts.
AffaMed Therapeutics maintains a strategic global presence with offices in Shanghai (China), Boston (USA), Hong Kong SAR, and Seoul (South Korea). This international footprint supports comprehensive global functions including R&D, clinical trial management across multiple regions, regulatory interactions with key health authorities (e.g., NMPA, FDA, MFDS), global business development, and strategic alliance management to advance its therapeutic pipeline in ophthalmology and CNS disorders worldwide.
Building 7, Lane 88, Shengrong Road, Pudong
Shanghai
Shanghai
China
Address: 800 Boylston Street, 16th Floor, Boston, MA 02199, USA
Facilitates collaboration with US-based research institutions, partners, and regulatory authorities like the FDA. Supports global clinical trial operations and talent acquisition in North America.
Address: Unit 702, 7/F, Lee Garden Two, 28 Yun Ping Road, Causeway Bay, Hong Kong
Supports AffaMed's corporate finance, legal, and business development activities in Asia, capitalizing on Hong Kong's status as a global financial center.
Address: 14F, Tower 8, 7 Jong-ro 5-gil, Jongno-gu, Seoul, Republic of Korea 03157
Drives AffaMed's clinical trial execution, regulatory submissions, and commercial preparation in South Korea, a significant market for innovative biopharmaceuticals in Asia.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AffaMed Therapeutics' leadership includes:
AffaMed Therapeutics has been backed by several prominent investors over the years, including:
In the past 12-18 months, AffaMed Therapeutics notably strengthened its executive team with the appointment of Dr. Eddy Wu as Chief Operating Officer. No major C-suite departures have been publicly announced during this period.
Discover the tools AffaMed Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While AffaMed Therapeutics's exact primary email format isn't publicly disclosed, companies of its nature commonly use patterns like first initial followed by last name, or first name separated from the last name by a period, at their domain affamed.com.
[first_initial][last_name]@affamed.com or [first_name].[last_name]@affamed.com
Format
jdoe@affamed.com or jane.doe@affamed.com
Example
75%
Success rate
AffaMed Therapeutics Website • March 26, 2024
AffaMed Therapeutics announced the dosing of the first patient in its China Phase III clinical trial (AM011-CN003) of DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for the treatment of ocular itching associated with allergic conjunctivitis. This is a key milestone for bringing DEXTENZA® to patients in China....more
AffaMed Therapeutics Website • January 16, 2024
AffaMed Therapeutics, in collaboration with Kissei Pharmaceutical Co., Ltd., announced the dosing of the first patient in a Phase I clinical trial of KDT-3594 in China. KDT-3594 is being investigated as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)....more
AffaMed Therapeutics Website • June 27, 2023
AffaMed Therapeutics announced the appointment of Dr. Eddy Wu as its Chief Operating Officer. Dr. Wu brings over two decades of experience in the biopharmaceutical industry, including operations, quality, manufacturing, and supply chain management....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AffaMed Therapeutics, are just a search away.